
<!DOCTYPE html>

<html lang="en">
<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ex.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="slide-ref">

<div id="popup"> 
<ol>
<li><span>KALETRA [package insert].</span></li> 
<li><span>IMS Health. 2002. </span></li>
<li><span>US Food and Drug Administration website. Approval of KALETRA 800/200 mg once-daily administration<br>for the treatment of HIV-infection in therapy-na&iuml;ve adult patients. Department of Health and Human Services.<br>April 29, 2005. Available at: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/<br>HIVandAIDSActivities/ucm124875.htm. Accessed March 14, 2011.</span></li>
<li><span>Data on file, AbbVie Inc.</span></li>
<li><span>US Food and Drug Administration website. FDA approval of new formulation of KALETRA. Department of<br>Health and Human Services. October 28, 2005. Available at: http://www.fda.gov/ForConsumers/ByAudience/<br>ForPatientAdvocates/HIVandAIDSActivities/ucm124816.htm. Accessed March 14, 2011.</span></li>
<li><span>US Food and Drug Administration website. Label and approval history. Available at: http://www.accessdata.fda.gov/<br>drugsatfda_docs/appletter/2007/021251s018,%20021906s007ltr.pdf. Accessed May 26, 2011.</span></li>
<li><span>US Food and Drug Administration website. New KALETRA (lopinavir/ritonavir) tablets and oral solution once daily<br>dosing regimen in certain adult patients. April 27, 2010. Available at: http://www.fda.gov/ForConsumers/<br>ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm209940.htm. Accessed April 19, 2011.</span></li>
<li><span> IMS Health, NPAâ„¢, September 2000-June 2012.</span></li>
</ol>



</div>

</body>
</html>